New combo therapy targets rare liver cancer in early trial
NCT ID NCT06027086
First seen Dec 17, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tests whether combining two drugs—DRP-104 (a glutamine blocker) and durvalumab (an immunotherapy)—is safe and can shrink tumors in people with advanced fibrolamellar carcinoma, a rare liver cancer. About 27 participants aged 12 and older whose cancer has worsened despite prior treatment will receive the drugs. The goal is to measure side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins SKCCC
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.